SN-38

For research use only.

Catalog No.S4908 Synonyms: NK012

35 publications

SN-38 Chemical Structure

CAS No. 86639-52-3

SN-38 (NK012) is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks. SN-38 induces autophagy.

Selleck's SN-38 has been cited by 35 publications

Purity & Quality Control

Choose Selective ADC Cytotoxin Inhibitors

Biological Activity

Description SN-38 (NK012) is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks. SN-38 induces autophagy.
Targets
Topo I [1]
(Cell-free assay)
In vitro

SN-38, a biological active metabolite of irinotecan hydrochloride (CPT-11). SN-38 causes the strongest inhibition of DNA topoisomerase I, followed by CPT and then CPT-11. CPT-11 dose dependently shifts the position of relaxed DNA in the direction of nicked DNA, but SN-38 and CPT shows no effect on the position of relaxed DNA. SN-38 dose-dependently and time-dependently inhibit DNA synthesis. Respective IC50 values of SN-38, in DNA synthesis is 0.077 μM. The inhibitory effect of SN-38 on RNA synthesis is less than that on DNA synthesis and it does not inhibit protein synthesis. SN-38 caused frequent DNA single-strand breaks in P388 cells. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human DU145 prostate cell line MkTIVJJwdGmoZYLheIlwdiCjc4PhfS=> MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JJBzd3O2YYTlJINmdGxibHnu[UwhUUN3ME2xN{BvVQ>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODR7OEKxOkc,OTB2OUiyNVY9N2F-
human MCF-7 breast cell line NYGwXVRuWHKxbHnm[ZJifGmxbjDhd5NigQ>? M{ewRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGMVch[nKnYYP0JINmdGxibHnu[UwhUUN3ME2wMlM4KM7:TR?= Ml3YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB2OUiyNVYoRjFyNEm4NlE3RC:jPh?=
human SKOV-3 ovarian cell line NFjLVm5Rem:uaX\ldoF1cW:wIHHzd4F6 NWrsc4NFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT29XNTNib4\hdolidiClZXzsJIxqdmVuIFnDOVA:OC55MjFOwG0> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODR7OEKxOkc,OTB2OUiyNVY9N2F-
human breast cancer cell line (SK-BR-3) NIHtUHREgXSxdH;4bYPDqGG|c3H5 MWXJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDidoVie3RiY3HuZ4VzKGOnbHygcIlv\SBqU1utRnIuOyluIFnDOVA:PCCwTR?= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTN|NEW2PUc,OTF|M{S1Olk9N2F-
human lung cancer cell line (H128) NHLE[XlEgXSxdH;4bYPDqGG|c3H5 M3Ttc2lvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIx2dmdiY3HuZ4VzKGOnbHygcIlv\SBqSEGyPEktKEmFNUC9OkBvVQ>? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTN|NEW2PUc,OTF|M{S1Olk9N2F-
human stomach cancer cell line (MKN45) NHjkfHhEgXSxdH;4bYPDqGG|c3H5 MkLGTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gd5RwdWGlaDDjZY5k\XJiY3XscEBtcW6nIDjNT241PSluIFnDOVA:QCCwTR?= NUn0U5ZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzN|Q2PjlpPkGxN|M1PTZ7PD;hQi=>
human ovarian cancer cell line (SK-OV-3) MWHDfZRwfG:6aXRCpIF{e2G7 MY\JckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsJIxqdmViKGPLMW9XNTNrLDDJR|UxRTFzIH7N NHvuXog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN|Q2Pjl:L3G+
human colon cancer cell line (WiDr) NWOwfWF[S3m2b4TvfIlkyqCjc4PhfS=> MmjJTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHygcIlv\SBqV3nEdkktKEmFNUC9NVQhdk1? M1TKNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
human lung cancer cell line (A549) M4fX[2N6fG:2b4jpZ:Kh[XO|YYm= MV7JckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDseY5oKGOjbnPldkBk\WyuIHzpcoUhMEF3NEmp NV;XVFZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzN|Q2PjlpPkGxN|M1PTZ7PD;hQi=>
NSCLC-H460 NIHQ[HBEgXSxdH;4bYPDqGG|c3H5 NHf0TYdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBvd25vc33hcIwu[2WubDDseY5oKGOjcnPpco9u[SClZXzsJIxqdmViSES2NEApVlOFTFOtTFQ3OCluIFnDOVA:QDBibl2= MoLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF3NkO5NlUoRjFzNU[zPVI2RC:jPh?=
PC-3 carcinoma cell line NEnwbZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXrDc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIHnubIljcXRiZ4Lve5RpKG:oIHj1cYFvKHC{b4P0ZZRmKFCFLUOgZ4Fz[2mwb33hJINmdGxibHnu[UwhUUN3ME2zOU43KG6P NGrpXlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUS1OFI{OCd-MUW0OVQzOzB:L3G+
human HCT116 colon cancer cell line NEHHdXFHfW6ldHnvckBie3OjeR?= MoPhTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiaIXtZY4hUEOWMUG2JINwdG:wIHPhcoNmeiClZXzsJIxqdmVuIFnDOVA:PyCwTR?= MmnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV6MEi0OVYoRjF3OEC4OFU3RC:jPh?=
human Bel-7402 liver cancer cell line NH35NlZHfW6ldHnvckBie3OjeR?= MWTJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCqdX3hckBD\WxvN{SwNkBtcX[ncjDjZY5k\XJiY3XscEBtcW6nLDDJR|UxRTNwMUmg{txO NV35b3M4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4NFg1PTZpPkG1PFA5PDV4PD;hQi=>
human tumor HL60 cell-line NGjueVFHfW6ldHnvckBie3OjeR?= MVOzJIRigXN? NWLHVopwUW5vdnn0do8hcW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIZweiCqdX3hckB1fW2xcjDIUFYxKGOnbHytcIlv\SC5YYOg[IV1\XKvaX7l[EB2e2mwZzDTVmIh[XO|YYmgZYZ1\XJiMzDkZZl{KG:oIHnuZ5Vj[XSrb36sJGlEPTB;MUmgcm0> MmjqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV7MUO5PVYoRjF3OUGzPVk3RC:jPh?=
human H460 cell Mm[yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{nLTGlvcGmkaYTpc44hd2ZiaIXtZY4hUDR4MDDj[YxtKGe{b4f0bEwhUUN3ME24NEBvVQ>? NUPWeVAxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NVM4ODZpPkG2PVE{PzB4PD;hQi=>
MDA-MB-435 MUHGeY5kfGmxbjDhd5NigQ>? M{n4fmlvcGmkaYTpc44h[WejaX7zeEBOTEFvTVKtOFM2KFNiaIXtZY4h[nKnYYP0JINidmOncjDj[YxteyCrbjD0bIUh[WK|ZX7j[UBw\iCjbHL1cYlvNCCLQ{WwJF0hOC5yMEWg{txONg>? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTB3MkiwNkc,OTFyNUK4NFI9N2F-
MDA-MB-435 M2rndWZ2dmO2aX;uJIF{e2G7 NFS4OFhKdmirYnn0bY9vKGGpYXnud5QhVUSDLV3CMVQ{PSCVIHj1cYFvKGK{ZXHzeEBk[W6lZYKgZ4VtdHNiaX6geIhmKHC{ZYPlcoNmKG:oIEOwJI1oN22OIFjTRUwhUUN3MDC9JFAvODVizszNMi=> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTB3MkiwNkc,OTFyNUK4NFI9N2F-
PC-6/SN2-5H NYTmcmVbTnWwY4Tpc44h[XO|YYm= M37CR3RRZ1SUQV7TVG9TXEWUOjD1dJRic2ViaX6gcYVu[nKjbnWgeoV{cWOuZTDmdo9uKFCFLU[vV24zNTWKIHPlcIx{NCCNbTC9JFQh|ryPLh?= M1G1elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzNki4PVgzLz5zMU[4PFk5OjxxYU6=
HT-29 M{XLfGZ2dmO2aX;uJIF{e2G7 M4XEfmlvKH[rdILvJIlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDDh[4FqdnO2IFjUMVI6KGi3bXHuJINwdG:wIHPhcoNmeiClZXzsd{whUUN3MDC9JFAvODJ5MzFOwG0v Mkj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4MUe5NlcoRjF{NkG3PVI4RC:jPh?=
SaoS2 NHnOTZFHfW6ldHnvckBie3OjeR?= NYDYWYFiXFChVGLBUnNRV1KWRWK6JIRzfWdicnXzbZN1[W6lZTjJcYF1cW6rYjDt[ZN6dGG2ZTmgbY4hSkOUUD3lfJBz\XO|aX7nJHNid1N{IHPlcIx{NCCLQ{WwJF0hOC5zN{[g{txONg>? NF3ucWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUC1PVg5OSd-MUWwOVk5QDF:L3G+
DU145 NIS2dVJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MXi5OkBpenN? MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy|IHHmeIVzKDl4IHjyd{whUUN3MDC9JFAvODB2IN88UU4> NGXkXVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK3OlE1OSd-MUiyO|YyPDF:L3G+
MIA PaCa NY\QV41PSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MVi5OkBpenN? MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2LQTDQZWNiKGOnbHzzJIFnfGW{IEm2JIhzeyxiSVO1NEA:KDBwMEC2JO69VS5? M{HHVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Mke2NVQyLz5zOEK3OlE1OTxxYU6=
HT29 NYe1UZY1SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MmrYPVYhcHK| M3i2VGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGSyPUBk\WyuczDh[pRmeiB7NjDodpMtKEmFNUCgQUAxNjBzMjFOwG0v M3LhT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Mke2NVQyLz5zOEK3OlE1OTxxYU6=
H460 NIO4VWpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NETPOosyKGi{ NFzR[pdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi0OlAh[2WubIOgZYZ1\XJiMTDodkBw\iCmcoXnJIV5eG:|dYLlJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyxiSVO1NEA:KDBwMkKg{txONg>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR{NEGzN{c,OTh2MkSxN|M9N2F-
HT29 Ml65RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MWixJIhz MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWMkmgZ4VtdHNiYX\0[ZIhOSCqcjDv[kBlenWpIHX4dI9{fXKnIH3lZZN2emWmIHHmeIVzKDd{IHjyd{whUUN3MDC9JFAvPjdizszNMi=> NF\xO2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESyOFE{Oyd-MUi0NlQyOzN:L3G+
HT29 MkexRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NWLUUGpLOSCqch?= MnPLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDCR3JRKG:4ZYLlfJBz\XO|aX7nJI1qfG:6YX70do9v\S2{ZYPpd5RidnRiaIXtZY4hUFR{OTDj[YxteyCjZoTldkAyKGi{IH;mJIRzfWdiZYjwc5N2emVibXXhd5Vz\WRiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNVEvPSEQvF2u M1LUU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEK0NVM{Lz5zOESyOFE{OzxxYU6=
H460 MlnaR5l1d3SxeHnjbZR6KGG|c3H5 M3rafmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGg1PjBiY3XscJMtKEmFNUCgQUAxNjJ{IN88UU4> NV62SHZ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0N|QyPTNpPkG4OFM1OTV|PD;hQi=>
A549 M1LsW2N6fG:2b4jpZ4l1gSCjc4PhfS=> NUPFcXM2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCkeTDTVmIhdWW2aH;kMEBKSzVyIE2gNE4xQCEQvF2u Ml7QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7OE[4NFcoRjF6OUi2PFA4RC:jPh?=
HT-29 MY\DfZRwfG:6aXPpeJkh[XO|YYm= Ml;MR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[nliU2LCJI1mfGixZDygTWM2OCB;IECuNVIh|ryPLh?= MkiwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7OE[4NFcoRjF6OUi2PFA4RC:jPh?=
PC6 M1e0[mFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MmfJOkBl[Xm| MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFNjDj[YxteyClYYLyfYlv\yCyUlOgZYZ1\XJiNjDkZZl{NCCLQ{WwJF0hOC5yMEC0N{DPxE1w M1[3U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
HCT116 NYrtNFRwSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MX6zJIRigXN? M{i4WGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEOg[IF6eyxiSVO1NEA:KDBwMECwOVUh|ryPLh?= M2GyclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
QG56 NIrNb4ZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NG\nN4k{KGSjeYO= MkW3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCTR{W2JINmdGy|IHHmeIVzKDNiZHH5d{whUUN3MDC9JFAvODB{ODFOwG0v M2WwUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
NCI-H460 MmKyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M2LXTFMh\GG7cx?= NYLpTWo5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCjZoTldkA{KGSjeYOsJGlEPTBiPTCwMlAxOzNizszNMi=> MkLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{NUS4OFMoRjF7MkW0PFQ{RC:jPh?=
BCRP NVXVNnptSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NG\Sbpg3KGSjeYO= NVjrdphESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Yh\XiycnXzd4lv\yCEQ2LQJINmdGy|IHHmeIVzKDZiZHH5d{whUUN3MDC9JFAvODB3MTFOwG0v M3;IUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
KB3-1 M2jpeGN6fG:2b4jpZ4l1gSCjc4PhfS=> NGmxdpU1KGSjeYO= MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRlMuOSClZXzsd{Bi\nSncjC0JIRigXNiYomgUXRVKG2ndHjv[EwhUUN3MDC9JFAvODB2IN88UU4> M1Ln[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{CzN|A3Lz5zOUOwN|MxPjxxYU6=
KBV1 Ml;6R5l1d3SxeHnjbZR6KGG|c3H5 MVO0JIRigXN? M{jIVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KE2GUkGgc5ZmemW6cILld5NqdmdiaIXtZY4hU0KYMTDj[YxteyCjZoTldkA1KGSjeYOgZpkhVVSWIH3leIhw\CxiSVO1NEA:KDBwMES2JO69VS5? NV;UPVEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNFM{ODZpPkG5N|A{OzB4PD;hQi=>
KBH5.0 NUGwcmtMS3m2b4TvfIlkcXS7IHHzd4F6 MVy0JIRigXN? M4r0TGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKFUmCgc5ZmemW6cILld5NqdmdiaIXtZY4hU0KKNT6wJINmdGy|IHHmeIVzKDRiZHH5d{BjgSCPVGSgcYV1cG:mLDDJR|UxKD1iMD6zJO69VS5? MmLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl|MEOzNFYoRjF7M{CzN|A3RC:jPh?=
NCI-H460 NWi5fFVbSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NX\vSGgxOSCqch?= M4ixVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg1PjBiY3XscJMh[W[2ZYKgd4hwenRidHXycUBmgHCxc4Xy[UBnd3JiMTDodkBu\WG|dYLl[EBi\nSncjC3NkBpenNiaX6g[JJ2\y2ocnXlJI1m\Gm3bTygTWM2OCB;IECuNVMh|ryPLh?= NXvmTVZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1N|A4OjBpPkG5OVMxPzJyPD;hQi=>
A549/ATCC M1XBW2FvfGm2dX3vdkBie3OjeR?= MUXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5M2FVS0NiY3XscJMh[nliU2LCJI1mfGixZDygTWM2OCB;IECuNFg5KM7:TT6= MlmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3NEG0PFMoRjF7NUSxOFg{RC:jPh?=
HT-29 NUnlVJJCSW62aYT1cY9zKGG|c3H5 M1\3VGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIJ6KFOUQjDt[ZRpd2RuIFnDOVAhRSByLkG3JO69VS5? MoSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3NEG0PFMoRjF7NUSxOFg{RC:jPh?=
gastric cancer cells MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUW3NkBpenN? MXfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDnZZN1emmlIHPhcoNmeiClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NEA:KDBwME[2JO69VS5? Mm\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OESwPFkoRjJyOEi0NFg6RC:jPh?=
lung cancer cells NVLSO|hvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYfDcnBLPzJiaILz M1zFUmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJIx2dmdiY3HuZ4VzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwJF0hOC5yNk[g{txONg>? MlntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OESwPFkoRjJyOEi0NFg6RC:jPh?=
colon cancer cells MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGLEcpI4OiCqcoO= MWXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUCgQUAxNjB4NjFOwG0v MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6NEC4PUc,OjB6OESwPFk9N2F-
HT-29 NUPkeY9yS3m2b4TvfIlkcXS7IHHzd4F6 MnfLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMtKEmFNUCgQUAxNjByNUmg{txONg>? Ml25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2N{C4OlQoRjJzNEewPFY1RC:jPh?=
A549 MXXDfZRwfG:6aXPpeJkh[XO|YYm= M1TaO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMtKEmFNUCgQUAxNjB2NzFOwG0v MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR5MEi2OEc,OjF2N{C4OlQ9N2F-
PC3 MYHDfZRwfG:6aXPpeJkh[XO|YYm= NWTNUlBjPzJiaILz MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOg[ZhxemW|c3nu[{BidHCqYUXi[ZRiOyCrboTl[5JqdiCjc4Pld5Nm\CCjczDj[YxtKHO3co\peoFtKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjByMk[g{txONg>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl3OUK0Okc,OjJ7NUmyOFY9N2F-
A2780 M2XWR2N6fG:2b4jpZ4l1gSCjc4PhfS=> MUK3NkBpenN? NWn5WpI3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNib4\ldoV5eHKnc4Ppcoch[WyyaHG1ZoV1[TNiaX70[YdzcW5iYYPz[ZN{\WRiYYOgZ4VtdCC|dYL2bZZidCCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yMEmg{txONg>? MmiwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NUmyOFYoRjJ{OUW5NlQ3RC:jPh?=
DU145 MWLDfZRwfG:6aXPpeJkh[XO|YYm= M2jDfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{NCCLQ{WwJF0hOC5yMzFOwG0v NXHKTpE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1O|g2PDVpPkKzOVc5PTR3PD;hQi=>
HT-29 MkPSR5l1d3SxeHnjbZR6KGG|c3H5 MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{whUUN3MDC9JFAvODNizszNMi=> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5OEW0OUc,OjN3N{i1OFU9N2F-
L1210 Mmj1R5l1d3SxeHnjbZR6KGG|c3H5 NGG5U5lEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBNOTJzMDDj[YxteyxiSVO1NEA:KDBwMESg{txONg>? NIrJT5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W3PFU1PSd-MkO1O|g2PDV:L3G+
DU145 MmfXR5l1d3SxeHnjbZR6KGG|c3H5 M{LoeFczKGi{cx?= MoLsR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR|UxKD1iMD6xNUDPxE1w M1\5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkKyPVgyLz5{M{[yNlk5OTxxYU6=
DU145 M2PZTmZ2dmO2aX;uJIF{e2G7 M1TPblAvOSC2bzCwMlUhfU1? M{[wZ|I1KGi{cx?= M2PrZmlvcGmkaYTpc44hd2ZiSFTBR{BqdiCqdX3hckBFXTF2NTDj[YxteyCjc4Pld5Nm\CCjczD1dJJm\3WuYYTpc44hd2ZicEKxe4FnOSCneIDy[ZN{cW:wIHH0JFAvOSC2bzCwMlUhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NGrPRok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[yNlk5OSd-MkO2NlI6QDF:L3G+
A549 M3vkbWN6fG:2b4jpZ4l1gSCjc4PhfS=> MUCzJIRigXN? NV;vR5NFS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB|IHThfZMh[nliU2LCJIF{e2G7LDDJR|UxKD1iMD6wNFI4OiEQvF2u MkTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mkm4O|AoRjJ2NUK5PFcxRC:jPh?=
HCT116 Ml\mR5l1d3SxeHnjbZR6KGG|c3H5 MkTZN{Bl[Xm| NXfDU4RIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEOg[IF6eyCkeTDTVmIh[XO|YYmsJGlEPTBiPTCwMlA{OSEQvF2u NEm2So49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
HT-29 NH2yTopEgXSxdH;4bYNqfHliYYPzZZk> M3TyS|Mh\GG7cx?= NUfNR|JCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiMzDkZZl{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNVA3PjdizszNMi=> Mn\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mkm4O|AoRjJ2NUK5PFcxRC:jPh?=
HCT116 NXfidJZ7S3m2b4TvfIlkcXS7IHHzd4F6 NXfPTXQ6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|LDDJR|UxKD1iMD6xOlYh|ryPLh?= NED6eGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
MDA-MB-231 M4qwPWN6fG:2b4jpZ4l1gSCjc4PhfS=> NFzYdWhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzMEBKSzVyIE2gNE4yPzZizszNMi=> NGjYeFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
A549 MlPQR5l1d3SxeHnjbZR6KGG|c3H5 MnfLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{whUUN3MDC9JFAvOjV7IN88UU4> NHi5Soc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
HEK293 M4fONmN6fG:2b4jpZ4l1gSCjc4PhfS=> NVHCc3FuPzJiaILz NX;UUHFQUW62cnnud4lkKGO7dH;0c5hq[2m2eTDh[4FqdnO2IFjFT|I6OyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVe1NEA:KDBwMEC1JO69VS5? MkfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{KwOVUoRjJ3MkeyNFU2RC:jPh?=
HCT116 MWfDfZRwfG:6aXPpeJkh[XO|YYm= M4rVZ|czKGi{cx?= MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFnDOVAhRSByLkCwOFI5KM7:TT6= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh|NUO1PUc,OjV6M{WzOVk9N2F-
HT-29 Ml7FR5l1d3SxeHnjbZR6KGG|c3H5 NWrPPXJlPzJiaILz NYm3dIFYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO|YYmsJGlEPTBiPTCwMlAyQDV2IN88UU4> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh|NUO1PUc,OjV6M{WzOVk9N2F-
HCT15 NH3pb|BEgXSxdH;4bYNqfHliYYPzZZk> NIjObm04OiCqcoO= NVzvV3A1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUWgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFA5KM7:TT6= M2P1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO|YxLz5{N{C2NFc3ODxxYU6=
U251 NHvPUnFEgXSxdH;4bYNqfHliYYPzZZk> MkDrO|IhcHK| NV\p[XhvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTJ3MTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxKD1iMD6wNlEh|ryPLh?= NILmdnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2NFc3OCd-MkewOlA4PjB:L3G+
U87MG M3jHcGN6fG:2b4jpZ4l1gSCjc4PhfS=> NF\6Om84OiCqcoO= M3LPOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkCzJO69VS5? M1nvbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO|YxLz5{N{C2NFc3ODxxYU6=
HT-29 MVfDfZRwfG:6aXPpeJkh[XO|YYm= NGLYN5Y4OiCqcoO= NUPUOXZ7S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFU1KM7:TT6= NUWyeGwzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewOlA4PjBpPkK3NFYxPzZyPD;hQi=>
MCF7 MnOyR5l1d3SxeHnjbZR6KGG|c3H5 NV20UYhxPzJiaILz NYWwS2NXS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxKD1iMD61NVUh|ryPLh?= M4e1XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO|YxLz5{N{C2NFc3ODxxYU6=
MDA-MB-231 M{fXXGN6fG:2b4jpZ4l1gSCjc4PhfS=> M2qxTFczKGi{cx?= M1nDOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFEvQTdizszNMi=> NHHzZZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2NFc3OCd-MkewOlA4PjB:L3G+
NCI-H460 MkfmR5l1d3SxeHnjbZR6KGG|c3H5 NX7IfXluOjRiaILz NV\5UJpZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVi0OlAh[2WubIOgdJJmfHKnYYTl[EBnd3JiMkSgbJJ{KHWwZHXyJI5wem2xeHnjJINwdmSrdHnvckBnd2yub4fl[EBjgSClb33wc5Vv\CC5YYPoc5V1KG2nYYP1doVlKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB3IN88UU4> M3HSdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WwPVk4Lz5{OEO1NFk6PzxxYU6=
NCI-H460 NXnTdJh2S3m2b4TvfIlkcXS7IHHzd4F6 MmPlNlQhcHK| MoewR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNicILleJJm[XSnZDDmc5IhOjRiaILzJJVv\GW{IHj5dI95cWNiY3;u[Il1cW:wIH\vcIxwf2WmIHL5JINwdXCxdX7kJJdie2ixdYSgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFYh|ryPLh?= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3MEm5O{c,Ojh|NUC5PVc9N2F-
HT-29 Mmm5R5l1d3SxeHnjbZR6KGG|c3H5 MVKyOEBpenN? NX3kdJk1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNicILleJJm[XSnZDDmc5IhOjRiaILzJJVv\GW{IH7vdo1wgGmlIHPvcoRqfGmxbjDmc4xtd3enZDDifUBkd22yb4Xu[EB4[XOqb4X0JI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCyMlc1KM7:TT6= MmD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|NUC5PVcoRjJ6M{WwPVk4RC:jPh?=
HT-29 NFrzN49EgXSxdH;4bYNqfHliYYPzZZk> M17LdFI1KGi{cx?= MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BxemW2cnXheIVlKG[xcjCyOEBpenNidX7k[ZIhcHmyb4jpZ{Bkd26maYTpc44h\m:ubH;3[YQh[nliY3;tdI92dmRid3HzbI92fCCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOy55MTFOwG0v M3rv[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WwPVk4Lz5{OEO1NFk6PzxxYU6=
NCI-H460 MnzKR5l1d3SxeHnjbZR6KGG|c3H5 NEPZdVg4OiCqcoO= M1HwXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KNE[wJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDy[YR2[3Srb36geY5l\XJiaInwc5hq[yClb37kbZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMES3JO69VS5? M2XGSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{SwOlE{Lz5{OEe0NFYyOzxxYU6=
NCI-H460 MlezR5l1d3SxeHnjbZR6KGG|c3H5 MWW3NkBpenN? MkW5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIILl[JVkfGmxbjD1coRmeiCwb4Ltc5hq[yClb37kbZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEWg{txONg>? MlnOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5NEC2NVMoRjJ6N{SwOlE{RC:jPh?=
HT-29 MVzDfZRwfG:6aXPpeJkh[XO|YYm= MmLBO|IhcHK| MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghemWmdXP0bY9vKHWwZHXyJI5wem2xeHnjJINwdmSrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4xQTZizszNMi=> NYHUTHc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OFA3OTNpPkK4O|QxPjF|PD;hQi=>
HT-29 M3rzfWN6fG:2b4jpZ4l1gSCjc4PhfS=> MWi3NkBpenN? M3n2TmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCC{ZXT1Z5Rqd25idX7k[ZIhcHmyb4jpZ{Bkd26maYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOTF7IN88UU4> NVOxOWNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OFA3OTNpPkK4O|QxPjF|PD;hQi=>
TC32 MnHTdWhVWyCjc4PhfS=> M1;6cJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy| MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 MV7xTHRUKGG|c3H5 NEDENpByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
DAOY NU\mdXBKeUiWUzDhd5NigQ>? M3r6epFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| MkHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 NI[wXo5yUFSVIHHzd4F6 MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| NUXYS5p6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 MXTxTHRUKGG|c3H5 MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD M2LYS5FJXFNiYYPzZZk> NV;SOWtReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| NEftc2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH MUjxTHRUKGG|c3H5 NYDQNXpneUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> MoHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 MkHSdWhVWyCjc4PhfS=> M{PBZZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) NIHuboZyUFSVIHHzd4F6 MkLOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| MoC1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 M3q1OJFJXFNiYYPzZZk> Mk\idWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 NX\ibYpteUiWUzDhd5NigQ>? M2GxPJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= NXzG[XNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 NY\P[Y9ieUiWUzDhd5NigQ>? NH7PSXByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1zMjDj[Yxtew>? NFPJWVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NFv4OodyUFSVIHHzd4F6 Mn3UdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? M2rWVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 MWrxTHRUKGG|c3H5 NY\aNpRxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= MkDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH NWjKeGlweUiWUzDhd5NigQ>? MlXMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2VSDDj[Yxtew>? MmG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh30 MYDxTHRUKGG|c3H5 MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh|MDDj[Yxtew>? NWPjXmFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 MoLzdWhVWyCjc4PhfS=> MVvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=> NVixPXdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30 M2HyNpFJXFNiYYPzZZk> M1HES5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM> NX3xNGszRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS MXvxTHRUKGG|c3H5 MkK0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWU0zKE:VIHPlcIx{ NX7FOpVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 MXnxTHRUKGG|c3H5 NETGR|VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{ MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 MU\xTHRUKGG|c3H5 M4n0UZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz NIHpUnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC NIP1PGRyUFSVIHHzd4F6 MlmxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= M2frc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 MnvBdWhVWyCjc4PhfS=> NE\oUYJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 M2DW[pFJXFNiYYPzZZk> M2XGeZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= NIjsNHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 MYnxTHRUKGG|c3H5 Ml7hdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? NF6yd5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
HCT116 Mn:wRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? Mnq5O|IhcHK| MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxKD1iMD6wNFA4QCEQvF2u M3XpOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUG1OFkzLz5|MEGxOVQ6OjxxYU6=
A549 Mkn2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MUC3NkBpenN? NIDMPFhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFAyPjJizszNMi=> Mke1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzMUW0PVIoRjNyMUG1OFkzRC:jPh?=
MCF7 Mn;DR5l1d3SxeHnjbZR6KGG|c3H5 NIH3RnQ4OiCqcoO= NFr5TVFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR|UxKD1iMD6wNFAyKM7:TT6= MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF4OUCzPEc,OzBzNkmwN|g9N2F-
A549 NGTrfHlEgXSxdH;4bYNqfHliYYPzZZk> NHTyN4k4OiCqcoO= NE\5T4xEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR|UxKD1iMD6yJO69VS5? NVy2WZhYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxOlkxOzhpPkOwNVY6ODN6PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Chk1 / Chk1 / Topo I ; 

PubMed: 18509065     


Log-phase Ovcar-5 cells were treated for 24 h with diluent (0.1% DMSO, lanes 1 and 6), gemcitabine at 12.5, 25, 50 or 100 nM (lanes 2-5, respectively), or SN-38 at 2.5, 5, 10, 20 and 40 nM in the absence (lanes 7-11) or presence (lanes 12-17) of 50 nM gemcitabine. At the end of the incubation, whole cell lysates were prepared, subjected to SDS-PAGE, transferred to nitrocellulose, and probed with reagents that recognize phospho-Ser345-Chk1, total Chk1, topo I or, as control, β-actin. Because of the limited number of lanes on our electrophoresis apparatus, lanes 1-5 and 6-17 represent two different membranes from the same experiment that were probed simultaneously.

18509065
Growth inhibition assay
Cell viability; 

PubMed: 25759163     


(A) Drug sensitivity towards SN‐38 and oxaliplatin for the parental and drug resistant cell lines. Cells were exposed to a range of drug concentrations for 48 h and cell viability was assessed by an endpoint MTT assay. Results of representative experiments are shown. Green (triangle) is the parental cell line, blue (diamond) the SN‐38 resistant cell line, and red (square) the oxaliplatin resistant cell line.

25759163
In vivo After oral dosing, peak SN-38 concentrations occurrs within 1 h, and the The percent unbound SN-38 lactone in murine plasma at 1000 ng/mL is 3.4 +/- 0.67%, whereas at 100 ng/mL the percent unbound is 1.18 +/- 0.14%. SN-38 lactone AUCs in micebearing human neuroblastoma xenografts are greater than in nontumor-bearing animals. [2]

Protocol

Kinase Assay:[1]
- Collapse

Topoisomerase I Assay:

One unit (the minimum amount for full relaxation of 0.5 μg SV40 DNA under the conditions of this study) of topoisomerase I, 0.5 μL of the test compounds, and 0.5μg SV40 DNA are added sequentially to the reaction buffer, which is composed of 25 mM Tris-HCl (pH 7.5), 50 mM KC1, 5 mM MgCl2, 0.25 mM EDTA disodium salt, 0.25 mM dithiothreitol, 15μg /mL bovine serum albumin, and 5% glycerol. Then, the reaction mixture (50 μL) is incubated for 10 min at 37 °C, and the reaction is terminated by treatment with 7.5 μL of a solution consisting of 1% sodium dodecyl sulfate, 20 mM EDTA disodium salt, and 0.5 mg/mL proteinase K for an additional 30 min at 37°C. The samples are mixed with 5 μL of the loading buffer containing 10 mM Na2HPO4, 31.3% sucrose, and 0.3% bromophenol blue. Relaxed (form Ir) DNA is separated from supercoiled (form I) and nicked (form II) DNA by electrophoresis on 0.8% agarose gel at 50 mA and 20 V for 17 h in the presence of 2 μg/mL chloroquine, 10 mM EDTA, 30 mM NaH2PO4, and 36 Mm Tris-HCl (pH 7.8). After electrophoresis, the gel is stained with 0.05% ethidium bromide and photographed with UV light (302 nm). The amount of DNA is quantified using a densitometer.
Cell Research:[3]
- Collapse
  • Cell lines: A-172, U-87, and LA-567
  • Concentrations: 0 -1000 nM
  • Incubation Time: 48 h
  • Method: MTT assay
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 21 mg/mL (53.51 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 392.4
Formula

C22H20N2O5

CAS No. 86639-52-3
Storage powder
in solvent
Synonyms NK012
Smiles CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04866641 Not yet recruiting Drug: T-1201 Injection 100 mg Kit Advanced Solid Tumor Taivex Therapeutics Corporation July 5 2021 Phase 1
NCT04617522 Recruiting Drug: Sacituzumab Govitecan-hziy Advanced or Metastatic Solid Tumor|Liver Failure Gilead Sciences April 6 2021 Phase 1
NCT03995706 Recruiting Drug: Sacituzumab Govitecan Glioblastoma The University of Texas Health Science Center at San Antonio|Gilead Sciences July 17 2019 Early Phase 1
NCT03245450 Completed Drug: Eribulin mesilate|Drug: Irinotecan hydrochloride Refractory or Recurrent Solid Tumors|Rhabdomyosarcoma|Non-Rhabdomyosarcoma Soft Tissue Sarcoma|Ewing Sarcoma Eisai Inc. February 22 2018 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy SN-38 | SN-38 supplier | purchase SN-38 | SN-38 cost | SN-38 manufacturer | order SN-38 | SN-38 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID